{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:58:48Z","timestamp":1768283928786,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Patient-Centered Clinical Research Coordinating Center (PACEN), funded by the Ministry of Health & Welfare, Republic of Korea","award":["HC21C0010"],"award-info":[{"award-number":["HC21C0010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Achieving target serum uric acid (SUA) levels is important in gout management. Guidelines recommend lowering SUA levels to\u2009&lt;\u20096\u00a0mg\/dL; however, many patients fail to reach this target, even with uric acid-lowering therapy (ULT). This study investigated clinical characteristics of target SUA achievers among Korean patients with gout. This study used data from the ULTRA registry, a nationwide inception cohort established in September 2021 that enrolls patients with gout who initiate ULT. Demographic, clinical, and laboratory data were collected at baseline; the 6-month follow-up. Patients were divided into two groups: target achievers (SUA level\u2009&lt;\u20096\u00a0mg\/dL at 6\u00a0months) and non-achievers. The mean participant (N\u2009=\u2009117) age was 56.1\u00a0years, and 88.0% were male. At 6\u00a0months, 83 patients (70.9%) reached target SUA levels. Target achievers had better drug adherence (\u2265\u200980%) to ULT (97.6% vs. 76.5%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) than non-achievers. Target non-achievers had a higher percentage of a family history of gout (32.4% vs. 10.8%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and less antihypertensive agent use (38.2% vs. 59.0%; <jats:italic>p<\/jats:italic>\u2009=\u20090.03) than target achievers. Multivariate regression analysis revealed that good adherence to ULT, the absence of a family history of gout, and antihypertensive agent use were key factors associated with achieving target SUA levels at 6\u00a0months.<\/jats:p>","DOI":"10.1038\/s41598-023-47790-6","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:02:08Z","timestamp":1700672528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9550-1048","authenticated-orcid":false,"given":"Hyunsue","family":"Do","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5192-6151","authenticated-orcid":false,"given":"Hyo Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6118-155X","authenticated-orcid":false,"given":"Byoongyong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-2190","authenticated-orcid":false,"given":"Chang-Nam","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-7939","authenticated-orcid":false,"given":"Sang-Hyon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-8571","authenticated-orcid":false,"given":"Se Rim","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0765-347X","authenticated-orcid":false,"given":"Ji Hyoun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-1415","authenticated-orcid":false,"given":"Min Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-7598","authenticated-orcid":false,"given":"Kichul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-1584","authenticated-orcid":false,"given":"Hyun-Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0104-4091","authenticated-orcid":false,"given":"Ran","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1981-742X","authenticated-orcid":false,"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3246-4435","authenticated-orcid":false,"given":"Joong Kyong","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-3978","authenticated-orcid":false,"given":"Seung-Geun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7351-3806","authenticated-orcid":false,"given":"Chang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7948-9624","authenticated-orcid":false,"given":"Kyeong Min","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-8328","authenticated-orcid":false,"given":"Ki Won","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"47790_CR1","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00296-017-3768-4","volume":"37","author":"JW Kim","year":"2017","unstructured":"Kim, J. W. et al. Prevalence and incidence of gout in Korea: Data from the national health claims database 2007\u20132015. Rheumatol. Int. 37, 1499\u20131506. https:\/\/doi.org\/10.1007\/s00296-017-3768-4 (2017).","journal-title":"Rheumatol. Int."},{"key":"47790_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 76, 29\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"47790_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4078\/jrd.2023.0029","volume":"30","author":"JJ Lee","year":"2023","unstructured":"Lee, J. J. et al. Korean guidelines for the management of gout. J. Rheum. Dis. 30, 141\u2013150. https:\/\/doi.org\/10.4078\/jrd.2023.0029 (2023).","journal-title":"J. Rheum. Dis."},{"key":"47790_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3346\/jkms.2014.29.5.657","volume":"29","author":"K Joo","year":"2014","unstructured":"Joo, K. et al. Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. J. Korean Med. Sci. 29, 657\u2013661. https:\/\/doi.org\/10.3346\/jkms.2014.29.5.657 (2014).","journal-title":"J. Korean Med. Sci."},{"key":"47790_CR5","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/art.40929","volume":"71","author":"N Dalbeth","year":"2019","unstructured":"Dalbeth, N. et al. Effects of Allopurinol dose escalation on bone erosion and urate volume in gout: A dual-energy computed tomography imaging study within a randomized, controlled trial. Arthritis Rheumatol. 71, 1739\u20131746. https:\/\/doi.org\/10.1002\/art.40929 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"47790_CR6","doi-asserted-by":"publisher","first-page":"e000075","DOI":"10.1136\/rmdopen-2015-000075","volume":"1","author":"EG Araujo","year":"2015","unstructured":"Araujo, E. G. et al. Tophus resolution with pegloticase: A prospective dual-energy CT study. RMD Open 1, e000075. https:\/\/doi.org\/10.1136\/rmdopen-2015-000075 (2015).","journal-title":"RMD Open"},{"key":"47790_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.semarthrit.2021.04.011","volume":"51","author":"CN Son","year":"2021","unstructured":"Son, C. N. et al. Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis. Semin. Arthritis Rheum. 51, 677\u2013684. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.04.011 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"47790_CR8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2169\/internalmedicine.1899-18","volume":"58","author":"A Katayama","year":"2019","unstructured":"Katayama, A. et al. Achievement of target serum uric acid levels and factors associated with therapeutic failure among Japanese men treated for hyperuricemia\/gout. Intern. Med. 58, 1225\u20131231. https:\/\/doi.org\/10.2169\/internalmedicine.1899-18 (2019).","journal-title":"Intern. Med."},{"key":"47790_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/14397595.2020.1800557","volume":"31","author":"JEC Quilisadio","year":"2021","unstructured":"Quilisadio, J. E. C., Salido, E. O. & Penserga, E. G. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines. Mod. Rheumatol. 31, 755\u2013761. https:\/\/doi.org\/10.1080\/14397595.2020.1800557 (2021).","journal-title":"Mod. Rheumatol."},{"key":"47790_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/ard.2008.092619","volume":"68","author":"JA Singh","year":"2009","unstructured":"Singh, J. A., Hodges, J. S. & Asch, S. M. Opportunities for improving medication use and monitoring in gout. Ann. Rheum. Dis. 68, 1265\u20131270. https:\/\/doi.org\/10.1136\/ard.2008.092619 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"47790_CR11","doi-asserted-by":"publisher","first-page":"e0193622","DOI":"10.1371\/journal.pone.0193622","volume":"13","author":"RJ Desai","year":"2018","unstructured":"Desai, R. J. et al. An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. PLoS One 13, e0193622. https:\/\/doi.org\/10.1371\/journal.pone.0193622 (2018).","journal-title":"PLoS One"},{"key":"47790_CR12","doi-asserted-by":"publisher","first-page":"e001015","DOI":"10.1136\/rmdopen-2019-001015","volume":"5","author":"F PerezRuiz","year":"2019","unstructured":"PerezRuiz, F. et al. Failure to reach uric acid target of < 0.36 mmol\/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open 5, e001015. https:\/\/doi.org\/10.1136\/rmdopen-2019-001015 (2019).","journal-title":"RMD Open"},{"key":"47790_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3899\/jrheum.190522","volume":"47","author":"JA Singh","year":"2020","unstructured":"Singh, J. A., Yang, S. & Saag, K. G. Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US veterans affairs gout cohort. J. Rheumatol. 47, 449\u2013460. https:\/\/doi.org\/10.3899\/jrheum.190522 (2020).","journal-title":"J. Rheumatol."},{"key":"47790_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/1471-2474-13-174","volume":"13","author":"N Dalbeth","year":"2012","unstructured":"Dalbeth, N. et al. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskelet. Disord. 13, 174. https:\/\/doi.org\/10.1186\/1471-2474-13-174 (2012).","journal-title":"BMC Musculoskelet. Disord."},{"key":"47790_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/pds.5127","volume":"30","author":"R Koto","year":"2021","unstructured":"Koto, R., Nakajima, A., Horiuchi, H. & Yamanaka, H. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. Pharmacoepidemiol. Drug Saf. 30, 157\u2013168. https:\/\/doi.org\/10.1002\/pds.5127 (2021).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"47790_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jbspin.2015.10.006","volume":"83","author":"T Pascart","year":"2016","unstructured":"Pascart, T. et al. GOSPEL 2: Colchicine for the treatment of gout flares in France\u2014a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age. Jt. Bone Spine 83, 687\u2013693. https:\/\/doi.org\/10.1016\/j.jbspin.2015.10.006 (2016).","journal-title":"Jt. Bone Spine"},{"key":"47790_CR17","first-page":"1813","volume":"33","author":"C Padang","year":"2006","unstructured":"Padang, C., Muirden, K. D., Schumacher, H. R., Darmawan, J. & Nasution, A. R. Characteristics of chronic gout in Northern Sulawesi, Indonesia. J. Rheumatol. 33, 1813\u20131817 (2006).","journal-title":"J. Rheumatol."},{"key":"47790_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cpt.89","volume":"97","author":"CC Wen","year":"2015","unstructured":"Wen, C. C. et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin. Pharmacol. Ther. 97, 518\u2013525. https:\/\/doi.org\/10.1002\/cpt.89 (2015).","journal-title":"Clin. Pharmacol. Ther."},{"key":"47790_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2147\/CEOR.S139939","volume":"9","author":"R Sheer","year":"2017","unstructured":"Sheer, R. et al. Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon. Outcomes Res 9, 629\u2013639. https:\/\/doi.org\/10.2147\/CEOR.S139939 (2017).","journal-title":"Clinicoecon. Outcomes Res"},{"issue":"3","key":"47790_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4081\/reumatismo.2019.1225","volume":"71","author":"CL Teh","year":"2019","unstructured":"Teh, C. L., Cheong, Y. K., Wan, S. A. & Ling, G. R. Treat-to-target (T2T) of serum urate (SUA) in gout: a clinical audit in real-world gout patients. Reumatismo 71(3), 154\u2013159 (2019).","journal-title":"Reumatismo"},{"key":"47790_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/ijpp\/riac025","volume":"30","author":"KA Sinnappah","year":"2022","unstructured":"Sinnappah, K. A., Stocker, S. L., Chan, J. S., Hughes, D. A. & Wright, D. F. B. Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: A systematic review. Int. J. Pharm. Pract. 30, 215\u2013225. https:\/\/doi.org\/10.1093\/ijpp\/riac025 (2022).","journal-title":"Int. J. Pharm. Pract."},{"key":"47790_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10067-020-05272-4","volume":"40","author":"M Fan","year":"2021","unstructured":"Fan, M. et al. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: A meta-analysis of randomized, controlled trials. Clin. Rheumatol. 40, 683\u2013692. https:\/\/doi.org\/10.1007\/s10067-020-05272-4 (2021).","journal-title":"Clin. Rheumatol."},{"key":"47790_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13075-019-1976-x","volume":"21","author":"N Liang","year":"2019","unstructured":"Liang, N. et al. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: A prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res. Ther. 21, 200. https:\/\/doi.org\/10.1186\/s13075-019-1976-x (2019).","journal-title":"Arthritis Res. Ther."},{"key":"47790_CR24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1055\/s-0042-113183","volume":"66","author":"S Ueno","year":"2016","unstructured":"Ueno, S. et al. Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: Cross-sectional cohort study. Drug Res. 66, 628\u2013632. https:\/\/doi.org\/10.1055\/s-0042-113183 (2016).","journal-title":"Drug Res."},{"key":"47790_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1185\/030079904125002982","volume":"20","author":"M Alderman","year":"2004","unstructured":"Alderman, M. & Aiyer, K. J. Uric acid: Role in cardiovascular disease and effects of losartan. Curr. Med. Res. Opin. 20, 369\u2013379. https:\/\/doi.org\/10.1185\/030079904125002982 (2004).","journal-title":"Curr. Med. Res. Opin."},{"key":"47790_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/08037051.2021.1996220","volume":"30","author":"D Zhang","year":"2021","unstructured":"Zhang, D., Huang, Q. F., Sheng, C. S., Li, Y. & Wang, J. G. Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers. Blood Press 30, 395\u2013402. https:\/\/doi.org\/10.1080\/08037051.2021.1996220 (2021).","journal-title":"Blood Press"},{"key":"47790_CR27","doi-asserted-by":"publisher","first-page":"d8190","DOI":"10.1136\/bmj.d8190","volume":"344","author":"HK Choi","year":"2012","unstructured":"Choi, H. K., Soriano, L. C., Zhang, Y. & Rodriguez, L. A. Antihypertensive drugs and risk of incident gout among patients with hypertension: Population based case-control study. BMJ 344, d8190. https:\/\/doi.org\/10.1136\/bmj.d8190 (2012).","journal-title":"BMJ"},{"key":"47790_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/1756-185X.14666","volume":"26","author":"KW Moon","year":"2023","unstructured":"Moon, K. W., Kim, M. J. & Shin, K. The aftermath of urate-lowering TheRApy in gout (ULTRA) registry: The first prospective observational multicenter cohort of Korean patients with gout. Int. J. Rheum. Dis. 26, 1015\u20131018. https:\/\/doi.org\/10.1111\/1756-185X.14666 (2023).","journal-title":"Int. J. Rheum. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47790-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47790-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47790-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:07:05Z","timestamp":1700672825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47790-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47790"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47790-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"31 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20511"}}